CEChinyere Elohor Egbordi

Chinyere Elohor Egbordi

*This is an algorithmically generated author record based on publicly available information.

Chinyere Elohor Egbordi has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Medical Nomenclature and Patient Understanding: Lessons from the Polycystic Ovary Syndrome to Polyendocrine Metabolic Ovarian Syndrome Transition

    by Uchechukwu Bethel Abioke, Chinyere Elohor Egbordi, Obiageri Ihuarulam Okeoma, Owolabi Ololade Funmilayo, Adibe Nnanyelugo Pius

    Background: Medical nomenclature can influence patients, clinicians, diagnostic accuracy, and health outcomes. On 12 May 2026, after a multi-year global consensus process, polycystic ovary syndrome (PCOS) was formally renamed polyendocrine metabolic ovarian syndrome (PMOS). The change reflected the recognition that the older term was scientifically imprecise and could contribute to delayed diagnosis, fragmented care, stigma, and limited patient understanding. Objectives: Using the PCOS-to-PMOS transition as a case study, this narrative review examines how an imprecise name may contribute to diagnostic delay, stigma, clinician confusion, and poorer outcomes. It synthesises evidence across five linked questions: how disease names shape patient understanding and health literacy; how they contribute to diagnostic delay and misdiagnosis; how they relate to stigma and psychosocial burden; how they influence clinician decision-making and care coordination; and what these effects imply for healthcare quality and patient safety. Methods: A narrative review of peer-reviewed literature, professional society publications, and grey literature was conducted using PubMed, Scopus, Web of Science, Google Scholar, and professional society websites. Search terms related to the phenomenon of interest, including “disease nomenclature,” “disease naming,” and “medical terminology,” were combined with terms describing its proposed effects, including “patient understanding,” “health literacy,” “diagnostic delay,” “stigma,” and “medical cognition,” and with condition-specific terms, including “PCOS,” “polycystic ovary syndrome,” and “PMOS.” Priority was given to studies addressing the effects of disease names on diagnosis, clinical outcomes, and health literacy. Findings: The evidence indicates that an imprecise name can weaken diagnostic accuracy through identifiable cognitive pathways. Cognitive load theory, conceptual anchoring, and semantic priming together explain how a name shapes patients’ and clinicians’ understanding. Historical reforms, from “hysteria” to specific diagnoses and from “Mongolism” to Down syndrome, show that more accurate naming has accompanied improved recognition and care. PCOS affects approximately one in eight women, or more than 170 million worldwide, yet up to 70% may remain undiagnosed or face diagnostic delays of several years. The PMOS revision illustrates how evidence-based terminology can be aligned with current scientific understanding. Conclusions: Medical terminology is not merely semantic; it shapes clinical reasoning, patient comprehension, and diagnostic and therapeutic pathways, with potential consequences for outcomes. The PCOS-to-PMOS transition shows that systematic, evidence-based nomenclature change is feasible and that disease names should reflect scientific understanding while supporting optimal care. Healthcare systems should treat nomenclature accuracy as a component of quality improvement and patient safety.

  • Optimising Insulin Therapy in Modern Type 2 Diabetes Care: A Narrative Review

    by Uchechukwu Bethel Abioke, Onyewuchi Onyinyechukwu Joy, Chinyere Elohor Egbordi, Osefanmen Matthew Enosolease

    Background: Type 2 diabetes mellitus is a chronic metabolic condition affecting millions of adults worldwide. Despite newer treatment modalities such as GLP-1 receptor agonists, SGLT2 inhibitors, and tirzepatide, insulin remains vital for many patients. This is particularly the case for those with advanced beta-cell dysfunction, severe hyperglycaemia, or inadequate glycaemic control despite non-insulin therapies. Objective: This narrative review outlines the changing landscape of insulin therapy for type 2 diabetes, and focuses on personalisation of treatment, combination therapy, minimising adverse events, digital technologies and safe de-intensification. Methods: Literature was reviewed from PubMed, Scopus, and Google Scholar, focusing mainly on clinical trials, systematic reviews, meta-analyses, major guidelines, and relevant expert reviews published between 2016 and 2026. Landmark older studies were included where clinically relevant. Key Findings: The use of insulin is still strongly influencing glycaemic control but is now more guided by new therapies and technologies. GLP-1 receptor agonists, SGLT2 inhibitors, and tirzepatide can be combined to lower the amount of insulin needed for treatment, help prevent weight gain, improve cardiometabolic outcomes, and decrease treatment burden in certain patients. New technologies such as smart insulin pens and digital titration devices facilitate more accurate insulin dosing and decrease the risk of hypoglycaemia. Patient-led titration and safe de-intensification are also important particularly for high-risk individuals for hypoglycaemia. Conclusion: Insulin therapy remains indispensable in type 2 diabetes care, but its optimal use now requires a more digitally supported, and patient-centred approach. The key concern is no longer whether insulin remains necessary, but how its use can be optimised to improve effectiveness and fit safely within modern type 2 diabetes care.

  • A Narrative Review of the Environmental and Public Health Implications of Carbon Sequestration in the Amazon Rainforest

    by Uchechukwu Bethel Abioke, Precious Mmesoma Umeasalugo, Chinyere Elohor Egbordi, Osasere Destiny Ikponmwosa, Elona Erezi

    The Amazon Rainforest stores an estimated 150–200 petagrams of carbon in its biomass and soils, making it the largest terrestrial carbon reservoir on Earth. This narrative review assesses the Amazon’s role in regulating global and regional climate, examines emerging evidence on the weakening of its carbon sink function, and evaluates the environmental and public health consequences of ongoing forest degradation. Drawing on research from 2015 to 2025, we analyze carbon sequestration processes, hydrological functions, including the “flying rivers” system, and feedback mechanisms driving parts of the southeastern Amazon toward a shift from carbon sink to carbon source. We also consider methodological differences in biomass estimation, particularly across remote sensing approaches, and their implications for carbon accounting. In addition, we highlight the health impacts of deforestation, including respiratory illness from wildfire smoke, heat-related illness, the spread of vector-borne diseases such as malaria and dengue, and risks to food and water security. We also assess current policy frameworks, including the Paris Agreement, REDD+, and national conservation laws. Overall, we argue that the Amazon is essential to planetary health, and that protecting it will require stronger and more effective governance, not just incremental changes to existing policies.